Industry News

Indonesian Food and Drug Administration (BPOM RIDirector Taruna IklarCadet PledgeOn Tuesday (2025Year12moon17(Japan)BPOMThe office building hosted an official delegation from the Guangxi Drug Administration of China. The meeting aimed to strengthen the strategic partnership between Indonesia and China in the areas of pharmaceutical and food regulation, in order to implement the directives of the Indonesian and Chinese presidents on deepening technological and industrial cooperation, particularly in the pharmaceutical sector and the assurance of quality for health products.

Taruna Iklar emphasized the importance of ongoing regulatory communication in supporting public health protection and enhancing the competitiveness of the pharmaceutical industry. She2025Year11He also expressed this view during his meeting with the head of the National Medical Products Administration in Beijing.

Indonesian Drug Authority (BPOM"We are ready to facilitate the product registration process in accordance with national standards, support increased exports of raw materials for traditional Indonesian medicines, participate in human resource capacity building programs, and develop joint work plans with the Guangxi Drug Administration," Taruna Iklar said.

The Chinese delegation was led by Li Yongqiang, Director of the Guangxi Drug Administration; Qiu Li, Director of the Examination and Registration Division of the Guangxi Drug Administration; Huang Zhe, Director of the Medical Device Supervision Division of the Guangxi Drug Administration; and Huang Zhongliang, Deputy Director of the Medical Device Testing Center of the Guangxi Drug Administration. Also present at the meeting were…Subur Abadi Entrance (ISA)SpecialistToni Halim BernekoandPT ONEChief Business Development OfficerSoelaiman Effendi。

Li Yongqiang, director of the Guangxi Drug Administration, explained that Guangxi is strategically located at the gateway between China and ASEAN, making it an ideal partner for regulatory cooperation and promoting regional cooperation.

Li Yongqiang stated that Guangxi has consistently been positioned by the Chinese central government as a pioneering region for promoting China-ASEAN cooperation. The cooperation between the Guangxi Drug Administration and the National Medical Products Administration aligns with Guangxi's strategic position and will contribute to strengthening China-ASEAN cooperation based on regulatory mutual trust.

Li Yongqiang added that the development of Guangxi's drug regulatory system and pharmaceutical industry includes strengthening Good Manufacturing Practices (GMP) for pharmaceuticals.GMPThe implementation of this mechanism is in line with international standards and also conforms to China's cooperation mechanism for drug inspection.PIC/SThese efforts demonstrate China's commitment to improving the quality and competitiveness of its pharmaceutical industry in global markets, including Indonesia.

Subsequently, the Guangxi Cosmetics Manufacturers Association submitted [the following documents] to the Indonesian Pharmaceuticals and Cosmetics Board. 5 The cooperation proposals include: promoting the entry of Guangxi cosmetics and other pharmaceuticals into the Indonesian market in accordance with the standards of the Indonesian Pharmaceutical and Cosmetic Committee; increasing the export of Indonesian traditional medicine raw materials to China; and Indonesia's participation in the ASEAN Outstanding Young Scientists Program./Young Scientists Exchange Program; Participation of the Indonesian Pharmaceuticals and Cosmetics Committee 2026 The China-ASEAN Pharmaceutical Cooperation and Development Summit Forum; and the formulation of follow-up work plans for Indonesia-China cooperation in drug and cosmetic regulation.

Taruna Iklar responded positively and candidly to the proposal. He stated that future cooperation between Indonesia and China covers multiple areas, including strengthening joint research, exploring clinical trial collaborations, expert exchanges, and developing evidence-based traditional Chinese medicine and Indonesian herbal remedies.

"In fact, the Indonesian National Drug Regulatory Agency (BPOMWe support collaborations that can increase public access to safe and high-quality medicines, while adhering to the principles of public health protection and regulatory compliance.BPOMWe are willing to work on strengthening Good Manufacturing Practices (GMP) for pharmaceuticals.GMP) and sharing in promoting drug information sharing and security (PIC/S“We will engage in technical dialogue based on our experiences during the process to enhance the regulatory capabilities of both countries,” Taruna Iklar concluded.

Indonesian Food and Drug Administration (BPOMIndonesia and China's National Medical Products Administration have agreed to establish technical cooperation in areas including research, clinical trials, development of standardized traditional Chinese medicine products, human resource capacity building, and enhanced regulatory dialogue. This meeting is expected to lay the foundation for strengthening sustainable cooperation and mutual respect for each other's regulatory systems. Furthermore, this meeting is an important step in deepening cooperation between the Indonesian Food and Drug Administration and China's drug regulatory agencies, and will also enhance Indonesia's role in the ASEAN drug regulatory dialogue.